Biotech Values

[oc631]

The simple answer is that it’s easier to design a safe and effective non-nuke than a safe and effective nuke. The former merely has to bind to the HCV polymerase, while the latter has to “trick” the polymerase into thinking it’s a bona fide HCV nuke rather than an impostor.

Do you see a future for the non-nuke class in HCV?